2020 ASCO Virtual Direct™ Highlights

 

2020 ASCO Virtual Direct™ Highlights
T

2020 ASCO Update on AML: Is Ivosidenib + BCL2 Inhibitor Venetoclax +/- Azacitidine Effective for Patients With IDH1-Mutated AML?

By 2020 ASCO Virtual Direct™ Highlights FEATURING Tapan Kadia
By 2020 ASCO Virtual Direct™ Highlights FEATURING Tapan Kadia
191 views
July 22, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

20:00
Exelixis

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam

Featured Video

20:09
AstraZeneca Oncology

Management Strategies for Anemia in First-line Maintenance Therapy f…

Feat. D. Czel, C. Arn
Hematologic Oncology
07:56
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Aggressive B-cell Lymphoma Highlights: Role of a Venetocla…

Feat. J. Soumerai
13:05
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Low-grade Lymphoma Highlights: Is CD19 CAR-T Axi-cel Activ…

Feat. J. Soumerai
03:26
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on Hodgkin Lymphoma: PD-1 mAb or Brentuximab Vedoti…

Feat. J. Soumerai
10:08
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on AML: Does Enasidenib + Azacitidine Significantly…

Feat. T. Kadia
08:39
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on AML: Is Ivosidenib + BCL2 Inhibitor Venetoclax +…

Feat. T. Kadia
05:04
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on AML: Does Venetoclax Added to Intensive Chemo + …

Feat. T. Kadia
05:12
2020 ASCO Virtual Direct™ Highlights

ASCO Update on CML: What Is the Optimal Ponatinib Dosing in Chronic …

Feat. T. Kadia
06:05
2020 ASCO Virtual Direct™ Highlights

2020 ASCO Update on AML: What Is the Optimal Dosing for AMG 330 Dose…

Feat. T. Kadia